F088 Skin Disease in Transplant Recipients and Immunosuppressed Patients
DESCRIPTION
Organ transplant recipients and other immunosuppressed patients have an increased risk of skin cancer development, progression, and death from skin cancer, as well as distinct presentations of inflammatory and infectious conditions. Dermatologists are uniquely positioned to care for these patients and optimize outcomes in the context of multidisciplinary care. This session will highlight key issues in the care of immunosuppressed patients, with a focus on prevention and management of multiple skin cancers, treatment of inflammatory and infectious skin disease, detection of skin lesions in underserved populations, and recognition and mitigation of treatment fatigue.
LEARNING OBJECTIVES
Summarize recommendations for screening, detection and management of multiple skin cancers in transplant and immunosuppressed patients, recognizing the role of multidisciplinary care.
Prescribe topical and systemic therapy for treatment of precursor lesions and prevention of skin cancer in transplant and immunosuppressed patients.
Diagnose inflammatory and infectious skin disease in transplant and immunosuppressed patients, and identify factors that contribute to treatment fatigue and discontinuation in this population.
SCHEDULE
1:00 PM
Introduction and Risk Assessment
Sean Christensen, MD, PhD, FAAD
1:15 PM
Drug Reactions and Infections
Melodi J. Whitley, MD, PhD, FAAD
1:30 PM
Inflammatory Skin Disease
Lihi Atzmony, MD, IFAAD
1:45 PM
Topical and Intra-Lesional Therapy
Amanda Rosenthal, MD, FAAD
2:00 PM
Under-Represented Cancers, Modifying Immunosuppression, and Treatment Fatigue
Stephanie Renae Jackson Cullison, MD, PhD, FAAD
2:15 PM
Systemic Chemoprevention
Lee Emerson Wheless, MD, PhD, FAAD
2:30 PM
Squamous Cell Carcinoma
Emily S Ruiz, MD, FAAD
2:45 PM
Treatment of Advanced Cancer
Nathalie C. Zeitouni, MD, FAAD
DIRECTOR
Sean Christensen, MD, PhD, FAAD
SPEAKERS
Lihi Atzmony, MD, IFAAD
Stephanie Renae Jackson Cullison, MD, PhD, FAAD
Amanda Rosenthal, MD, FAAD
Emily S Ruiz, MD, FAAD
Lee Emerson Wheless, MD, PhD, FAAD
Melodi J. Whitley, MD, PhD, FAAD
Nathalie C. Zeitouni, MD, FAAD
DISCLOSURES
Lihi Atzmony, MD, IFAAD
No financial relationships exist with ineligible companies.
Sean Christensen, MD, PhD, FAAD
Castle Biosciences – Advisory Board(Honoraria); inhibitor therapeutics – Advisory Board(No Compensation Received); Sol-Gel Technologies – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Stephanie Renae Jackson Cullison, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Amanda Rosenthal, MD, FAAD
No financial relationships exist with ineligible companies.
Emily S Ruiz, MD, FAAD
Almirall – Consultant (1099 relationship)(Fees); Castle Biosciences, Inc – Investigator(Grants/Research Funding); Checkpoint Therapeutics – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Fees), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees), Consultant (1099 relationship)(Fees);
Lee Emerson Wheless, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Melodi J. Whitley, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Nathalie C. Zeitouni, MD, FAAD
Alpha Tau Medical – Investigator(Grants/Research Funding); Biofrontera AG – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Castle Biosciences – Investigator(Grants/Research Funding), Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Replimune – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);